Posted by Michael Wonder on 23 Apr 2025
Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with haemophilia A or B
22 April 2025 - The MHRA has approved the medicine marstacimab (Hympavzi) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35kg with haemophilia A and B.
This medicine is the first of its kind to work by targeting a protein in the blood clotting process.
